Products
Doxetaxel
Annual sales worldwide US$ 3,0 bn
Chemical Name
(2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5b-20-epoxy-1,2a,4,7b,10b,13a-hexahydro tax-11-en-9-one 4-acetate 2-benzoate
General Indications
- Breast cancer optionally in combination with Doxorubicin and Cyclophosphamide
- Non-small cell lung cancer optionally in combination with Cisplatin
- Prostate cancer
- Gastric adenocarcinoma
- Head and neck cancer
- Ovarian cancer
Innovator/Marketeer
- Aventis (Taxotere)
- Sanofi-Aventis (Taxotere)
| Dosage Form | Route | Active Ingredient | Strengths |
|---|---|---|---|
| Concentrate (single vial) | Injectable | Docetaxel | 20, 40 mg/ml |
| Concentrate (twin vial) | Injectable | Docetaxel | 20 mg/ml |